06Jul 2023
Survodutide Leads To Striking Weight Loss In People Who Are Overweight Or
Obese: Phase 2 Trial

Survodutide Leads To Striking Weight Loss In People Who Are Overweight Or Obese: Phase 2 Trial

A Phase 2 study presented at the American Diabetes Association's Scientific Sessions revealed that survodutide, a drug developed by Boehringer Ingelheim and Zealand Pharma, showed superior efficacy compared to a placebo in treating obesity and overweight individuals without type 2 diabetes. The study involved 387 adults across various regions and demonstrated a clear dose-response regarding weight loss, with about 40% of participants achieving a weight reduction of at least 20%. Survodutide, a dual glucagon-like peptide-I (GLP-I) and glucagon receptor agonist, received Fast Track Designation from the US FDA for patients with non-alcoholic fatty liver disease. The study's findings support further investigation in larger Phase 3 trials.

  • #endo-diabetology

Like

Save

Share